Trastuzumab has significantly advanced the clinical management of patients with HER2+ breast cancer by prolonging disease-free survival and overall survival in patients with early-stage breast cancer, and progression-free survival and overall survival in patients with metastatic breast cancer [70, 71]. Here, ERBB2 is linked to breast cancer.